Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA

Xiao,Ke; Ouyang,Zhengxiao; Tang,Hui‑Huan

doi:10.3892/ol.2018.8840

Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA

Authors:
- Ke Xiao
- Zhengxiao Ouyang
- Hui‑Huan Tang
View Affiliations

Affiliations: Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China, Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: May 30, 2018 https://doi.org/10.3892/ol.2018.8840
Pages: 1841-1848

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate whether the proliferation and metastasis of hilar cholangiocarcinoma cells can be suppressed and whether apoptosis can be induced by small interfering RNA (siRNA) repression of vascular endothelial growth factor (VEGF). siRNA sequences targeting the VEGF gene were designed and the human hilar cholangiocarcinoma QBC939, HCCC‑9810 and RBE cell lines were transfected with VEGF‑siRNA plasmids for 48 h. Reverse transcription‑quantitative polymerase chain reaction and western blotting measured the levels of VEGF‑A, VEGF‑C and matrix metalloproteinase 2 (MMP2) mRNA expression and protein content. The cell invasion potential was evaluated using the Transwell invasion and migration assay and the MTT assay was employed to detect the proliferation of hilar cholangiocarcinoma cells. Flow cytometry was used to quantify cell apoptosis and necrosis. Following the transfection of VEGF‑siRNA, a significant reduction of mRNA and protein levels of VEGF‑A, VEGF‑C and MMP2 was observed in the hilar cholangiocarcinoma cells. The invasion, migration and proliferation of tumor cells were also notably decreased. The rate of tumor cell apoptosis was increased in the VEGF‑siRNA group (15.42%) compared with the non‑siRNA control (2.22%) and the negative control (2.71%) groups. It was concluded that blocking the expression of VEGF via VEGF‑siRNA effectively inhibited the invasion, migration and proliferation, and induced apoptosis in hilar cholangiocarcinoma cells. These observations suggested that targeting VEGF with RNAi may be an effective therapeutic strategy for treating hilar cholangiocarcinoma.

View Figures

View References

1	Blechacz B and Gores GJ: Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
2	Ito F, Cho CS, Rikkers LF and Weber SM: Hilar cholangiocarcinoma: Current management. Ann Surg. 250:210–218. 2009. View Article : Google Scholar : PubMed/NCBI
3	Blendis L and Halpern Z: An increasing incidence of cholangiocarcinoma: Why? Gastroenterology. 127:1008–1009. 2004. View Article : Google Scholar : PubMed/NCBI
4	Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, Sripa B and Hong ST: Epidemiology of cholangiocarcinoma: An update focusing on risk factors. Cancer Sci. 101:579–585. 2010. View Article : Google Scholar : PubMed/NCBI
5	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global Cancer Statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
6	Feige JJ: Tumor angiogenesis: Recent progress and remaining challenges. Bull Cancer. 97:1305–1310. 2010.(In French). PubMed/NCBI
7	Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, Ota H, Yoshioka S, Kato H, Damdinsuren B, et al: Angiogenesis in cholangiocellular carcinoma: Expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep. 15:525–532. 2006.PubMed/NCBI
8	Thelen A, Scholz A, Weichert W, Wiedenmann B, Neuhaus P, Gessner R, Benckert C and Jonas S: Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma. Am J Gastroenterol. 105:1123–1132. 2010. View Article : Google Scholar : PubMed/NCBI
9	Halper J: Growth factors as active participants in carcinogenesis: A perspective. Vet Pathol. 47:77–97. 2010. View Article : Google Scholar : PubMed/NCBI
10	Appelmann I, Liersch R, Kessler T, Mesters RM and Berdel WE: Angiogenesis inhibition in cancer therapy: Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: Biological functions and role in malignancy. Recent Results Cancer Res. 180:51–81. 2010. View Article : Google Scholar : PubMed/NCBI
11	Zhou J and Tang HH: Significance and expression of microvessel density, vascular endothelial growth factor and matrix metalloproteinases 2 in cholangiocarcinoma. Chin J Gen Surg. 12:122–124. 2003.(In Chinese).
12	Das S, Ladell DS, Podgrabinska S, Ponomarev V, Nagi C, Fallon JT and Skobe M: Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases. Cancer Res. 70:1814–1824. 2010. View Article : Google Scholar : PubMed/NCBI
13	Achen MG and Stacker SA: Molecular control of lymphatic metastasis. Ann NY Acad Sci. 1131:225–234. 2008. View Article : Google Scholar : PubMed/NCBI
14	Vázquez-Vega S, Contreras-Paredes A, Lizano-Soberón M, Amador-Molina A, García-Carrancá A, Sánchez-Suárez LP and Benítez-Bribiesca L: RNA interference (RNAi) and its therapeutic potential in cancer. Rev Invest Clin. 62:81–90. 2010.(In Spanish). PubMed/NCBI
15	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lares MR, Rossi JJ and Ouellet DL: RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28:570–579. 2010. View Article : Google Scholar : PubMed/NCBI
17	Sui G, Soohoo C, Affar el B, Gay F and Shi Y, Forrester WC and Shi Y: A DNA vector based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA. 99:5515–5520. 2002. View Article : Google Scholar : PubMed/NCBI
18	Yu JY, DeRuiter SL and Turner DL: RNA interfering by expression of short interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA. 99:6047–6052. 2002. View Article : Google Scholar : PubMed/NCBI
19	McManus MT and Sharp PA: Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 3:737–747. 2002. View Article : Google Scholar : PubMed/NCBI
20	Macedo F, Ladeira K, Longatto-Filho A and Martins SF: gastric cancer and angiogenesis: Is VEGF a useful biomarker to assess progression and remission? J Gastric Cancer. 17:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
21	Chen J, Wu H, Han D and Xie C: Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett. 231:169–175. 2004. View Article : Google Scholar
22	Queiroga FL, Pires I, Parente M, Gregório H and Lopes CS: COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer. Vet J. 189:77–82. 2011. View Article : Google Scholar : PubMed/NCBI
23	Botelho F, Pina F and Lunet N: VEGF and prostatic cancer: A systematic review. Eur J Cancer Prev. 19:385–392. 2010. View Article : Google Scholar : PubMed/NCBI
24	Eibl G, Bruemmer D, Okada Y, Duffy JP, Law RE, Reber HA and Hines OJ: PGE (2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 306:887–897. 2003. View Article : Google Scholar : PubMed/NCBI
25	Shah MA: The development of bevacizumab in noncolorectal gastrointestinal malignancies: Gastroesophageal, pancreatic, and hepatocellular carcinoma. Clin Adv Hematol Oncol. 12:239–246. 2014.PubMed/NCBI
26	Bhardwaj A, Kaur J, Wuest F and Knaus EE: Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: Synthesis and biological studies. ChemMedChem. 9:109–116, 240. 2014. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M and Vauthey JN: Hilar cholangiocarcinoma: Expert consensus statement. HPB (Oxford). 17:691–699. 2015. View Article : Google Scholar : PubMed/NCBI
29	Tsao JI, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M, Miyachi M, Kanai M, Uesaka K, Oda K, et al: Management of Hilar Cholangiocarcinoma: Comparison of an American and a Japanese experience. Ann Surg. 232:166–174. 2000. View Article : Google Scholar : PubMed/NCBI
30	McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ and Kay MA: RNA interference in adult mice. Nature. 418:38–39. 2002. View Article : Google Scholar : PubMed/NCBI
31	Petrocca F and Lieberman J: Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol. 29:747–754. 2011. View Article : Google Scholar : PubMed/NCBI
32	Addepalli MK, Ray KB, Kumar B, Ramnath RL, Chile S and Rao H: RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther. 17:352–359. 2010. View Article : Google Scholar : PubMed/NCBI
33	Cuevas EP, Escribano O, Monserrat J, Martínez-Botas J, Sánchez MG, Chiloeches A, Hernández-Breijo B, Sánchez-Alonso V, Román ID, Fernández-Moreno MD and Guijarro LG: RNAi-mediated silencing of insulin receptor substrate-4 enhances actinomycin D- and tumor necrosis factor-alpha-induced cell death in hepatocarcinoma cancer cell lines. J Cell Biochem. 108:1292–1301. 2009. View Article : Google Scholar : PubMed/NCBI
34	Varnholt H: The role of microRNAs in primary liver cancer. Ann Hepatol. 7:104–113. 2008.PubMed/NCBI
35	Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 99:11393–11398. 2002. View Article : Google Scholar : PubMed/NCBI
36	Ylä-Herttuala S: Gene therapy with vascular endothelial growth factors. Biochem Soc Trans. 37:1198–1200. 2009. View Article : Google Scholar : PubMed/NCBI
37	Grünewald FS, Prota AE, Giese A and Ballmer-Hofer K: Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta. 1804:567–580. 2010. View Article : Google Scholar : PubMed/NCBI
38	Geva R, Prenen H, Topal B, Aerts R, Vannoote J and van Cutsem E: Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: The role of anti-VEGF and anti-EGFR antibodies. J Surg Oncol. 102:937–945. 2010. View Article : Google Scholar : PubMed/NCBI
39	Vermeulen PB, van Golen KL and Dirix LY: Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: A review of the current knowledge. Cancer. 116(Suppl 11): S2748–S2754. 2010. View Article : Google Scholar
40	Winder T and Lenz HJ: Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology. 138:2163–2176. 2010. View Article : Google Scholar : PubMed/NCBI
41	Kluger MS and Colegio OR: Lymphangiogenesis linked to VEGF-C from tumor-associated macrophages: Accomplices to metastasis by cutaneous squamous cell carcinoma? J Invest Dermatol. 131:17–19. 2011. View Article : Google Scholar : PubMed/NCBI
42	Beeghly-Fadiel A, Shu XO, Lu W, Long J, Cai Q, Xiang YB, Zheng Y, Zhao Z, Gu K, Gao YT and Zheng W: Genetic variation in VEGF family genes and breast cancer risk: A report from the Shanghai Breast Cancer Genetics Study. Cancer Epidemiol Biomark Prev. 20:33–41. 2011. View Article : Google Scholar
43	Nakatani H, Akimori T, Takezaki Y and Hanazaki K: Vascular endothelial growth factors and their receptors in the novel human cell line, HN-Eso-1, established from esophageal spindle cell carcinoma. J Med Invest. 57:232–236. 2010. View Article : Google Scholar : PubMed/NCBI
44	Park KS, Kim SJ, Kim KH and Kim JC: Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 26:391–397. 2011. View Article : Google Scholar : PubMed/NCBI
45	Overall CM and Dean RA: Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 25:69–75. 2006. View Article : Google Scholar
46	Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI